Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females 17 years of age or older.~* Stable cancer-related pain.~* Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain.~* Experiencing 1-4 episodes of breakthrough pain per day.~* Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.~Exclusion Criteria:~* Have previously been exposed to EN3267.~* Are pregnant or lactating.~* Have uncontrolled or rapidly escalating pain.~* Have any clinically significant condition that would, in the investigator's opinion, preclude participation in the study or compromise data collection. These conditions may include cardiopulmonary disease, and/or neurologic/psychologic conditions.~* Are scheduled to take MAOIs (monoamine oxidase inhibitors) during the study.~* Are scheduled to receive anti-neoplastic therapy that, in the investigator's opinion, will influence assessment of breakthrough pain.~* Are scheduled to receive an investigational drug other than EN3267 during the course of the study.~* Have hypersensitivity, allergy or contraindication to fentanyl.~* Have significant prior history of substance abuse or alcohol abuse.~* Would have difficulty complying with the protocol, as assessed by the investigator.~* Are unable to read, write, or comprehend the English language in order to complete diaries.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sublingual fentanyl tablet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).